09:32 AM EST, 11/05/2024 (MT Newswires) -- CRISPR Therapeutics ( CRSP ) reported a Q3 net loss Tuesday of $1.01 per diluted share, narrowing from a loss of $1.41 a year earlier.

Analysts polled by Capital IQ expected a net loss of $1.38 per share.

Revenue for the quarter ended Sept. 30 was $602,000. No revenue was reported a year earlier.

Analysts polled by Capital IQ expected $7.1 million.

Price: 50.65, Change: -0.11, Percent Change: -0.22